Drug
MK-8189 clinical trials
Also written MK-8189 and Elpipodect.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
- MK-8189
- 11
Other names
Studies by the year they started
11 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses MK-8189 is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT06273774Written as Elpipodect
- A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)CompletedPhase 1Merck Sharp & Dohme LLCNCT05893862Written as Elpipodect
- A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT05406440Written as Elpipodect
- An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)CompletedPhase 2Merck Sharp & Dohme LLCNCT03055338Written as Elpipodect
- Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)CompletedPhase 1Merck Sharp & Dohme LLCNCT05227118Written as Elpipodect
- A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)CompletedPhase 1Merck Sharp & Dohme LLCNCT04676425Written as Elpipodect
- Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT02181803Written as Elpipodect
- Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT04624243Written as Elpipodect
- Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)CompletedPhase 1Merck Sharp & Dohme LLCNCT04506905Written as Elpipodect
- A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)CompletedPhase 1Merck Sharp & Dohme LLCNCT06626464Written as [14C]Elpipodect
- A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)CompletedPhase 1Merck Sharp & Dohme LLCNCT03565068Written as MK-8189
Given in every arm · 1 — MK-8189 is usual care beside what is tested
Codes
What other systems call MK-8189 · ClinicalTrials.gg INT002043
- MeSH (NLM) C000729358MK-8189One source ClinicalTrials.gov
- UNII (FDA) 7M430JI73BMK-8189Confirmed FDA, Wikidata
- Wikidata Q123746506MK-8189Confirmed FDA, Wikidata
- DrugBank DB19153One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729358 | MK-8189 | One source ClinicalTrials.gov |
| UNII (FDA) | 7M430JI73B | MK-8189 | Confirmed FDA, Wikidata |
| Wikidata | Q123746506 | MK-8189 | Confirmed FDA, Wikidata |
| DrugBank | DB19153 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.